Massive Selloff-ATHX Investors Cash-In on News of Lower Valued Secondary Offering
When Steve Brozak performs diligence on biotech stocks, he's always looking for an angle. Brozak, president and managing director at WBB Securities, wants to see how new technology platforms
When progress is made in drug development, value is created. Investors recognize that progress by purchasing shares in companies when milestones—which act as catalysts—are met. The
Company chart and information is provided by TradingView based on 15-minute-delayed data.
Athersys Inc is a clinical-stage biotechnology company. It is focused on developing novel and proprietary therapies in the areas where there is a significant unmet medical need, particularly in the regenerative medicine area. The firm's main product is Multistem cell therapy. Its current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.
| Website: | www.athersys.com |
| Email: | ir@athersys.com |
| Main Phone: | +1 216 431-9900 |
| Address: | 3201 Carnegie Avenue |
| State: | OH |
| City / Town: | Cleveland |
| Country: | US |
| Postal Code: | 44115-2634 |
| Exchange: | NSC |
| CEO: | William Lehmann |
| Employees: | 97 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Massive Selloff-ATHX Investors Cash-In on News of Lower Valued Secondary Offering
When Steve Brozak performs diligence on biotech stocks, he's always looking for an angle. Brozak, president and managing director at WBB Securities, wants to see how new technology platforms
When progress is made in drug development, value is created. Investors recognize that progress by purchasing shares in companies when milestones—which act as catalysts—are met. The
Clinical trial data can move a stock price like virtually nothing else on Wall Street. Given the proclivity for volatility, investing in small- and mid-cap biotech is definitely not for the faint
Readers will likely remember the political fights that have happened over the past decade around the use of embryonic stem cells. Stem cells are so-called “pluripotent” cells -- they
News that the US government would pay off a sizable chunk of its debt and the possible marriage of two major drug conglomerates saw the S&P and DJIA rise as the markets continue their run
Shares in clinical-stage biotechnology company Athersys (ATHX) plunged over 55 percent on Monday following the release of clinical data from its clinical study using the company’s MultiStem
Of the many themes that propelled the biotech sector to record returns in 2013, regenerative medicine and therapeutics targeting cancer were front and center. In this interview with The Life
The U.S. healthcare system is untenable, says Steve Brozak, president of WBB Securities. The solution-oriented Brozak is on the hunt for biotech and medical device companies that fit a new
At www.ValuEngine.com we show that the Medical sector 10.1% overvalued with the Medical Biomed/Genetics 11.9% overvalued. All 14 stocks in today’s table have complete ValuEngine data and have
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
